Optimi Health Corp. is a commercial-stage pharmaceutical company specializing in psychedelic drug products for regulated mental health therapies. The company focuses on the manufacture and distribution of GMP-grade MDMA and natural psilocybin in finished-dose capsule form, produced at its Health Canada-licensed, GMP-compliant facilities in British Columbia, Canada. Optimi Health Corp. supplies both active pharmaceutical ingredients and finished dosage forms to clinical and therapeutic programs, serving psychiatrists, clinics, and research organizations operating within controlled regulatory frameworks. Its products are used in authorized treatment settings, including programs in Australia under the Authorized Prescriber Scheme and in Canada via special access pathways. Operating in the emerging medical psychedelics and mental health treatment ecosystem, Optimi Health Corp. plays a specialized role in providing pharmaceutical-grade, standardized psychedelic formulations that support evidence-based therapeutic use in conditions such as post-traumatic stress disorder and treatment-resistant depression. Incorporated in 2020 and headquartered in British Columbia, the company positions itself within the intersection of pharmaceuticals, mental health care, and regulated psychedelic-assisted therapy.